Literature DB >> 9174653

Attenuation of contractile responses to sympathetic co-transmitters in veins from subjects with essential hypertension.

H Lind1, D Erilnge, J Brunkwall, L Edvinsson.   

Abstract

Neuropeptide Y (NPY), noradrenaline (NA) and ATP are cotransmitters of the sympathetic nervous system and exert vasocontractile effects. The aim of this study was to determine the role of these sympathetic co-transmitters in human hypertension. Subcutaneous vessels from 12 patients with essential hypertension and 12 matched controls were studied in vitro. Vascular contractile responses to NPY, NA, alpha,beta-methylene ATP (alpha,beta-mATP) and potassium were studied in isolated arteries and veins (diameter 0.1-1.1 mm) with intact endothelium. The dilatory effect of acetylcholine was used to test the endothelial function. There was no difference in potency (pD2) or contractile response to NPY, NA or alpha,beta-mATP between hypertensive and control arteries. In veins, however, the contractile response to NPY was significantly reduced in hypertensives and the responses to NA were unchanged. Furthermore, the sensitivity (pD2) to alpha,beta-mATP was significantly reduced in veins from hypertensives. There was no difference in the dilatory response to acetylcholine between the hypertensives and the controls, neither in the arteries nor in the veins, indicating that the observed changes in vascular reactivity to NPY, NA and alpha,beta-mATP were not endothelium-dependent. In conclusion, the postjunctional contractile effect of NPY and sensitivity (pD2) to alpha,beta-mATP, co-transmitters of the peripheral sympathetic nervous system, are attenuated in veins in essential hypertension.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9174653     DOI: 10.1007/BF02267749

Source DB:  PubMed          Journal:  Clin Auton Res        ISSN: 0959-9851            Impact factor:   4.435


  57 in total

1.  Neuropeptide Y (NPY)-like immunoreactivity in peripheral noradrenergic neurons and effects of NPY on sympathetic function.

Authors:  J M Lundberg; L Terenius; T Hökfelt; C R Martling; K Tatemoto; V Mutt; J Polak; S Bloom; M Goldstein
Journal:  Acta Physiol Scand       Date:  1982-12

2.  Vascular reactivity of normotensive and hypertensive human arteries.

Authors:  O Thulesius; J E Gjores; E Berlin
Journal:  Gen Pharmacol       Date:  1983

3.  Effect of increased availability of endothelium-derived nitric oxide precursor on endothelium-dependent vascular relaxation in normal subjects and in patients with essential hypertension.

Authors:  J A Panza; P R Casino; D M Badar; A A Quyyumi
Journal:  Circulation       Date:  1993-05       Impact factor: 29.690

4.  Effects of neuropeptide Y on cardiac performance and renal blood flow in conscious normotensive and renal hypertensive rabbits.

Authors:  R B Minson; R J McRitchie; M J Morris; J P Chalmers
Journal:  Clin Exp Hypertens A       Date:  1990

5.  Human neuropeptide Y Y1 receptor antisense oligodeoxynucleotide specifically inhibits neuropeptide Y-evoked vasoconstriction.

Authors:  D Erlinge; L Edvinsson; J Brunkwall; F Yee; C Wahlestedt
Journal:  Eur J Pharmacol       Date:  1993-08-10       Impact factor: 4.432

6.  Neuropeptide Y-like immunoreactivity and hypertension.

Authors:  D Erlinge; R Ekman; T Thulin; L Edvinsson
Journal:  J Hypertens       Date:  1992-10       Impact factor: 4.844

7.  Sympathetic activation after two weeks of nifedipine treatment in primary Raynaud's patients and controls.

Authors:  J Leppert; H Nilsson; U Myrdal; L Edvinsson; T Hedner; I Ringqvist
Journal:  Cardiovasc Drugs Ther       Date:  1993-12       Impact factor: 3.727

8.  Vasomotor changes in isolated coronary arteries from diabetic rats.

Authors:  A Sjögren; L Edvinsson
Journal:  Acta Physiol Scand       Date:  1988-11

9.  Blunted effects of endothelin upon small subcutaneous resistance arteries of mild essential hypertensive patients.

Authors:  E L Schiffrin; L Y Deng; P Larochelle
Journal:  J Hypertens       Date:  1992-05       Impact factor: 4.844

10.  High risk of cerebro-cardiovascular morbidity in well treated male hypertensives. A retrospective study of 40-59-year-old hypertensives in a Swedish primary care district.

Authors:  L Lindholm; G Ejlertsson; B Scherstén
Journal:  Acta Med Scand       Date:  1984
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.